ARHGAP18 Activators
ARHGAP18 activators comprise a selection of chemical compounds that indirectly enhance the functional activity of ARHGAP18 by influencing various signaling pathways and cellular processes related to cytoskeletal dynamics. For instance, Lithium Chloride, by activating the Wnt/β-catenin signaling through GSK-3β inhibition, may create an environment conducive to ARHGAP18's regulatory effect on the actin cytoskeleton. Similarly, PIP3 is integral to actin cytoskeleton reorganization, and its increased presence could indirectly activate ARHGAP18 by amplifying signaling pathways that modulate cytoskeletal rearrangement. Forskolin raises cAMP levels, which in turn activate PKA; this activation could propagate signaling events leading to the enhancement of ARHGAP18's involvement in stress fiber formation. Inhibitors of Rho-associated kinases, such as Y-27632 and GSK269962A, reduce tension within the cytoskeleton, thereby potentially facilitating the activity of ARHGAP18 in maintaining cytoskeletal integrity. Calpeptin and Jasplakinolide, by modulating the stability of the cytoskeleton, may also indirectly augment the activity of ARHGAP18, emphasizing its role in actin filament regulation.
Additionally, through their targeted actions on various Rho family GTPases, CCG-1423, NSC 23766, and ML141 can induce changes in the actin cytoskeleton that indirectly promote ARHGAP18 activity. CCG-1423's inhibition of Rho-mediated transcription, NSC 23766's blockade of Rac1, and ML141's inhibition of Cdc42 all contribute to a cellular state that can potentiate ARHGAP18's regulatory functions. Prostaglandin E2, by engaging its receptors, triggers signaling cascades that lead to cytoskeletal alterations, which could enhance ARHGAP18's role as a GTPase activator protein. Phalloidin, through actin filament stabilization, and Jasplakinolide, by inducing actin polymerization, indirectly support ARHGAP18's activity by affecting the dynamics of the actin architecture it regulates. Collectively, these activators operate through diverse mechanisms to facilitate the enhancement of ARHGAP18-mediated cytoskeletal organization, without necessitating direct activation or upregulation of its expression.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium Chloride activates the Wnt/β-catenin signaling pathway by inhibiting GSK-3β. ARHGAP18 can be affected by changes in this pathway due to its role in cytoskeletal dynamics. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin elevates cAMP levels, which indirectly enhances ARHGAP18's role in stress fiber formation by stimulating PKA, potentially leading to the activation of ARHGAP18. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor that can lead to actin cytoskeleton rearrangement, indirectly impacting ARHGAP18 activity by reducing tension within the cytoskeleton where ARHGAP18 functions. | ||||||
Calpeptin | 117591-20-5 | sc-202516 sc-202516A | 10 mg 50 mg | $121.00 $456.00 | 28 | |
Calpeptin is a calpain inhibitor. By stabilizing the cytoskeleton, it may indirectly enhance ARHGAP18's activity, as ARHGAP18 is involved in modulating the actin cytoskeleton. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
CCG-1423 inhibits Rho-mediated gene transcription. By modulating RhoA activity, it can affect ARHGAP18's role in cytoskeletal dynamics indirectly, as ARHGAP18 is a Rho GTPase activating protein. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
NSC 23766 is a Rac1 inhibitor. By inhibiting Rac1, cytoskeletal changes occur that may indirectly increase ARHGAP18 activity due to its role in the RhoA signaling pathway. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
PGE2 can lead to actin cytoskeletal changes through its receptors. ARHGAP18, as a GTPase activator protein, may be indirectly activated as part of the signaling events triggered by PGE2. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
ML141 is a Cdc42 inhibitor. Inhibition of Cdc42 can lead to alterations in cell shape and motility, which could indirectly enhance the activity of ARHGAP18 in the actin cytoskeleton regulation. | ||||||
GSK 269962 | 850664-21-0 | sc-363279 sc-363279A | 10 mg 50 mg | $300.00 $1000.00 | 1 | |
GSK269962A is a ROCK inhibitor similar to Y-27632. It may indirectly impact ARHGAP18 function by promoting cell relaxation and decreasing cytoskeletal tension, where ARHGAP18 is active. | ||||||
Phalloidin | 17466-45-4 | sc-202763 | 1 mg | $234.00 | 33 | |
Phalloidin stabilizes actin filaments. This stabilization can potentially enhance ARHGAP18's regulatory effect on the actin cytoskeleton by increasing the substrate availability for its activity. | ||||||